Last reviewed · How we verify
COVID-19 exposure — Competitive Intelligence Brief
phase 2
Infectious Diseases
Biologic
Live · refreshed every 30 min
Target snapshot
COVID-19 exposure (COVID-19 exposure) — Barts & The London NHS Trust. This drug aims to stimulate the immune system to fight COVID-19 infection.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| COVID-19 exposure TARGET | COVID-19 exposure | Barts & The London NHS Trust | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- COVID-19 exposure CI watch — RSS
- COVID-19 exposure CI watch — Atom
- COVID-19 exposure CI watch — JSON
- COVID-19 exposure alone — RSS
Cite this brief
Drug Landscape (2026). COVID-19 exposure — Competitive Intelligence Brief. https://druglandscape.com/ci/covid-19-exposure. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing